Thalidomide for Control Delayed Vomiting in Cancer Patients Receiving Chemotherapy. | [Journal of College of Physicians and Surgeons--Pakistan : JCPSP • 2016]

Author(s):

1. Zhengxiang Han: Department of Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221000, P.R. China

2. Xuan Sun: Department of Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221000, P.R. China

3. Guan Jiang: Department of Dermatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221000, P.R. China

4. Xiuping Du: Department of Oncology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221000, P.R. China

Abstract:

Objective: To explore the efficacy and safety of thalidomide for the treatment of delayed vomiting, induced by chemotherapy in cancer patients. Study Design: Randomized, double-blind controlled study. Place and Duration of Study: The Oncology Department of Affiliated Hospital of Xuzhou Medical University, Jiangsu Xuzhou, China, from January 2012 to January 2014. Methodology: A total of 78 cancer patients, who had delayed vomiting observed from 24 hours to 1 week after chemotherapy, were included in the study. Patients were divided in a treatment group (40 patients, 51.28%) and a control group (38 patients, 48.71%). The treatment group received thalidomide at an oral dose of 100 mg per night; 50 mg was added daily up to a dose of 200 mg per night, if the curative effect was suboptimal and the medicine was tolerated. Both the treatment and the control groups received a drip of 10 mg azasetron 30 minutes before chemotherapy. The control group only proportions of antiemetic effects and adverse reactions were compared using the ?2 test. Antiemetic effects and adverse reactions were assessed from Odds Ratios (OR) with 95% Confidence Intervals(95% CI). Results: The effective control rate of delayed vomiting in the treatment group was significantly higher than that in the control group (?2=5.174, p=0.023). No significant difference was found between the two groups in other adverse effects of chemotherapy. Karnofsky scores or the overall self-evaluation of the patients (p>0.05). Conclusion: Thalidomide can effectively control the delayed vomiting of cancer patients receiving chemotherapy and the adverse reactions of the agent can be tolerated.

Page(s): 900-903

DOI: DOI not available

Published: Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 26, Issue: 11, Year: 2016

Keywords:

Keywords are not available for this article.

References:

[1] NomanAS,KoideN,HassanF,I-E-KhudaI,DagvadorjJ,TumurkhuuG, 2009.Thalidomide inhibits lipopolysaccharide - induced tumor necrosis factor-alpha production via downregulation of My D88 expression,Innate Immun 15 33 -41

[2] Eleutherakis-PapaiakovouV,BamiasA,DimopoulosMA, 2004.Thalidomide in cancer medicine,Ann Oncol 15 1151 -60

[3] HanZX,XuJ,WangHM,MaJ,SunX,DuXP, 2014.Antiemetic role of thalidomide in a rat model of cisplatin-induced emesis,Cell Biochem Biophys 70 361 -5

[4] MillerAB,HoogstratenB,StaquetM,WinklerA, 1981.Reporting results of cancer treatment,Cancer 47 207 -14

[5] SanmukhaniJJ,PawarP,MittalR, 2014.Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: The Indian experience,South Asian J Cancer 3 132 -7

[6] BroderMS,FariaC,PowersA,SunderjiJ,CherepanovD., 2014.The impact of 5-HT3RA use on cost and utilization in patients with chemotherapy-induced nausea and vomiting: Systematic Review of the Literature,Am Health Drug Benefits 7 171 -82

[7] GrunbergSM,DeusonRR,MavrosP,GelingO,HansenM,CrucianiG, 2004.Incidence of chemotherapy-induced nausea and vomiting after modern antiemetics,Cancer 100 2261 -8

[8] JordanK,SippelC,SchmollHJ, 2007.Guidelines for antiemetie treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations,Oncologist 12 1143 -50

[9] PoonKS,UnMK,LowXH,CheungYT,YapKY,ChanA, 2013.Impact of cancer-related fatigue on chemotherapy-induced nausea and vomiting in Asian cancer patients,Pharmacoepidem Dr S 22 1345 -51

[10] YasuiK,KobayashiN,YamazakiT,AgematsuK., 2005.Thalidomide as an immunotherapeutic agent: The effects on neutrophilmediated inflammation,Curr Pharm Des 11 395 -401

[11] LeeSM,RuddR,WollPJ,OttensmeierC,GilliganD,PriceA, 2005.Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer,J Clin Oncol 27 5248 -54

[12] LeeSM,WollPJ,RuddR,FerryD,O'BrienM,MiddletonG, 2009.Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: A randomized, doubleblind, placebo-controlled trial,J Natl Cancer Inst 101 1049 -57

[13] WatanabeR,TokuhiraM,KizakiM., 2013.Current approaches for the treatment of multiple myeloma,Int J Hematol 97 333 -44

[14] HeskethPJ,Van BelleS,AaproM,TattersallFD,NaylorRJ,HargreavesR, 2003.Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists,Eur J Cancer 39 1074 -80

Citations

Downloads

Views